Similar articles

• The need for a post-marketing surveillance program in Israel.

  Shemer J. Shemer J. Isr Med Assoc J. 1999 Oct;1(2):98-9. Isr Med Assoc J. 1999. PMID: 10731306 No abstract available.
• The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).

  Doshi A. Doshi A. Seton Hall Law Rev. 2007;37(2):625-60. Seton Hall Law Rev. 2007. PMID: 17294569 No abstract available.
• Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.

  Noah BA, Brushwood DB. Noah BA, et al. J Health Law. 2000 Summer;33(3):383-454. J Health Law. 2000. PMID: 11184355
• Post-market approval surveillance: a call for a more integrated and comprehensive approach.

  Mehran R, Leon MB, Feigal DA, Jefferys D, Simons M, Chronos N, Fogarty TJ, Kuntz RE, Baim DS, Kaplan AV. Mehran R, et al. Circulation. 2004 Jun 29;109(25):3073-7. doi: 10.1161/01.CIR.0000134694.78653.B6. Circulation. 2004. PMID: 15226222 Review. No abstract available.
• Adverse drug reactions: a review of relevant factors.

  Ajayi FO, Sun H, Perry J. Ajayi FO, et al. J Clin Pharmacol. 2000 Oct;40(10):1093-101. J Clin Pharmacol. 2000. PMID: 11028248 Review.